Chemo-free in Older (65) Node-Positive ER+/HER2- Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2035-05-15
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged \>65 years) with lymph node-positive, HR+/HER2- breast cancer.